TARRYTOWN, N.Y., Feb. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol ...
Regeneron has received FDA approval for Arcalyst (rilonacept injection) for the treatment of cryopyrin-associated periodic syndromes (CAPS) in patients ≥12 years of age. Arcalyst, an interleukin-1 (IL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results